Bilirubin Blood Test Market Growth, Demand & Size by 2034

Coverage: By : Test Type (Total Serum Bilirubin Test, Direct/Conjugated Bilirubin Test, Indirect/Unconjugated Bilirubin Test); Product Type (Consumables, Instruments); Age Group (Pediatric/Infants, Adults); End User (Hospitals, Clinics and Others), and Geography (North America, Europe, Asia Pacific, and South and Central America)

Historic Data: 2021-2024 | Base Year: 2025 | Forecast Period: 2026-2034
  • Status : Data Released
  • Report Code : TIPRE00018027
  • Category : Life Sciences
  • No. of Pages : 150
  • Available Report Formats : pdf-format excel-format
  • Last update date : November 12, 2026
Bilirubin Blood Test Market Growth, Demand & Size by 2034
Report Date: November 12, 2026   |   Report Code: TIPRE00018027 Email: sales@theinsightpartners.com

2025 Market Size

US$ 1.5 Bn

Base year value

2034 Forecast

US$ 2.72 Bn

Projected by 2034

CAGR 2026-2034

6.86 %

Growth rate

Addressable Market

US$ 19.09 Bn

(2026-2034)

The bilirubin blood test market was valued at US$ 1.5 Billion in 2025 and is projected to reach US$ 2.72 Billion by 2034, registering a CAGR of 6.86% during 2026–2034. Growth is driven by routine liver function testing, neonatal jaundice assessment, rising diagnosis of hepatobiliary disorders, and greater availability of automated clinical chemistry systems. Recurring demand for reagents and improved access to diagnostic services further support market expansion.

North America remains a major diagnostic market, with the bilirubin blood test market size expected to expand at a CAGR of ~6% through 2034. The region benefits from extensive hospital and reference laboratory networks, established newborn bilirubin assessment protocols, and high clinical chemistry automation. Demand is also supported by frequent hepatic panel testing and investment in integrated analyzers that enable laboratories to process chemistry and immunoassay workloads efficiently.

Bilirubin Blood Test Market Assessment and Insights

Regional Outlook

  • North America: ~38% of the global bilirubin blood test market share in 2025 | ~6% CAGR through 2034. Market position: North America leads through high laboratory testing intensity, established neonatal care pathways, extensive analyzer penetration, and strong demand for hepatic panels across hospitals and independent laboratories.
  • US: ~85% of North American market revenue in 2025 | ~6% CAGR through 2034. Market position: The US leads North America due to its large hospital network, widespread predischarge newborn assessment, automated laboratory infrastructure, and concentration of clinical diagnostic suppliers.
  • Europe: ~28% of the global market in 2025 | ~6% CAGR through 2034. Market position: Europe maintains a mature position supported by universal healthcare access, standardized laboratory practices, aging populations, and established diagnostic markets in Germany, the UK, France, Italy, and Spain.
  • Asia Pacific: ~25% of the global market in 2025 | ~9% CAGR through 2034. Market position: Asia Pacific is the fastest-growing region as China, Japan, India, South Korea, and Australia expand diagnostic capacity, maternal care, local manufacturing, and automated testing access.

Segment Outlook

  • Consumables: ~68% Share in 2025 | ~7% CAGR through 2034. Market position: Consumables lead because bilirubin reagents, calibrators, controls, cuvettes, and related materials generate recurring expenditure across installed laboratory and point-of-care testing systems.
  • Pediatric/Infants: ~35% Share in 2025 | ~8% CAGR through 2034. Market position: Pediatric and infant testing is advancing rapidly due to structured newborn jaundice assessment, follow-up monitoring, growing institutional birth coverage, and demand for low-volume blood sampling.

Competitive Coverage

Koninklijke Philips N.V., Beckman Coulter, Inc., Thermo Fisher Scientific Inc., Randox Laboratories Ltd., F. Hoffmann-La Roche Ltd, Drägerwerk AG & Co. KGaA, Ginevri S.r.l., Advanced Instruments, LLC, Reichert, Inc., Siemens Healthineers AG

Methodology

The Insight Partners follows Data Collection & Secondary Research, Primary Research, Data Analysis, and Data Triangulation & Final Review to validate market estimates and insights.

Source: The Insight Partners' analysis based on proprietary research, government publications, company annual reports, investor presentations, industry databases, and expert interviews.

The process of bilirubin measurement has progressed from simple visual inspection through colorimetric assays to more sophisticated techniques like serological tests, liver function panel analysis, and non-invasive screening for babies. Some of the current features in laboratory technology that enable efficient handling of huge quantities of work with little manual input include liquid-stable reagents, auto-calibration capability, barcode scanning, and middleware interface. As far as babies are concerned, transcutaneous instruments are employed in the preliminary assessment of risk, but serological testing is critical for diagnosis and decision-making.

Until 2034, new diagnosis networks will provide testing services not only in leading metropolises. Development investments will be directed to small-sized chemical analyzers, portable bilirubin devices, reagent production in local laboratories, and equipment appropriate for various throughputs. The emphasis made by regulatory authorities on analytical validation, quality management, traceability, and patient safety will make producers with clinical validation results more competitive. Maternal public health programs and wider liver disease testing can help introduce bilirubin testing in underdeveloped healthcare systems.

Bilirubin Blood Test Market Report Scope

Report Attribute Details
Market size in 2025 US$ 1.5 Billion
Market Size by 2034 US$ 2.72 Billion
Global CAGR (2026 - 2034)6.86%
Historical Data 2021-2024
Forecast period 2026-2034
Inquire More about this report.
Inquire More

Bilirubin Blood Test Market Analysis

The principal mechanism supporting bilirubin blood test market growth is the recurring need to assess bilirubin in newborn care, hepatic panels, hemolytic conditions, and hepatobiliary disease management. The value chain encompasses assay manufacturers, optical and clinical chemistry instrument producers, raw-material suppliers, quality-control providers, distributors, hospitals, and laboratories. Consumables create recurrent revenue, while instrument purchases depend on testing volume, workflow integration, service coverage, and total ownership cost.

The supply needs vary depending on the testing site. Central laboratories require systems that operate at high throughput levels and have stable reagent supplies, whereas neonatal units prefer quick tests, small sample sizes, and easy-to-use point-of-care instruments. The manufacturers are required to provide consumables for their analyzers and open systems reagents. The availability of distribution is critical in emerging countries since temperature control, technical support, and availability of spare parts affect the use of the equipment.

The bilirubin blood test market analysis shows the competition that exists between integrated diagnostic firms and specialized firms dealing with neonatal or laboratory equipment. Beckman Coulter, Inc., F. Hoffmann-La Roche Ltd, and Siemens Healthineers AG take care of the automated laboratories, while Koninklijke Philips N.V., Drägerwerk AG & Co. KGaA, Ginevri S.r.l., Advanced Instruments, LLC, and Reichert, Inc. offer the instruments. Randox Laboratories Ltd. and Thermo Fisher Scientific Inc. offer reagents and laboratory technology.

Investment is shifting towards platforms with scalability, better optical measurement systems, greater efficiency in reagents, connections to information systems, and service-based business models. Products can be positioned on the basis of care setting rather than simply their ability to measure. Large-scale labs focus on automation and cost-per-test, while neonatal departments place greater importance on portability and minimizing patient discomfort.

● REPORT CUSTOMIZATION

Tailor This Report To Align With Your Specific Business Requirements

This report can be customized to align precisely with your business objectives, scope, and target markets. Customization options include tailored segmentation, geography, competitive analysis, and strategic insights to support informed decision-making.

Customize This Report →

WHAT YOU CAN ADJUST

  • ● Segmentations
  • ● Geography
  • ● Competitive Analysis
  • ● Language Preferences

Bilirubin Blood Test Market: Strategic Insights

bilirubin-blood-test-market
Download Free sample to check more details about report.
This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
Download Free Sample

Regional Insights

North America bilirubin blood test market

North America accounted for ~38% of global revenue in 2025 and is projected to register a ~6% CAGR through 2034. The regional bilirubin blood test market share is supported by established hospital laboratories, high clinical chemistry analyzer penetration, structured neonatal care, and routine use of hepatic panels. Healthcare providers use serum testing for liver assessment and treatment monitoring, while noninvasive instruments support newborn risk evaluation.

The advantage of Canada is its centralized system of laboratories in provinces and uniform hospital testing processes. The advantage of Mexico is growth potential through private chain of diagnostic centers, maternity centers, and updating clinical laboratories. In this region, buying will be based on parameters like analytical precision, amount of specimens, time frame, expendables cost, networking capabilities, quality control compatibility, and availability of service.

U.S. bilirubin blood test market

The US represented ~85% of North American revenue in 2025 and is anticipated to expand at a ~6% CAGR through 2034. Need exists for newborn bilirubin testing, emergency medicine, oncology, gastroenterology, general health screening, and management of liver or blood disorders. Professional practice recommendations call for systematic testing of babies at risk of severe hyperbilirubinemia and testing whenever there is early onset of jaundice.

The nation has key players that cater to the needs of laboratory and neonatal sectors. Beckman Coulter, Inc., F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, and Randox Laboratories Ltd. are key competitors in laboratory diagnostics, while dedicated devices take care of bedside testing. An integrated delivery network promotes the use of standard reagents, normal reference ranges, and test equipment platforms in multiple hospitals. There exists a demand for standardized devices owing to the existence of networked laboratories.

Europe bilirubin blood test market

Europe generated ~28% of worldwide revenue in 2025 and is expected to grow at a ~6% CAGR through 2034. The market has advanced laboratory infrastructure and in vitro diagnostic requirements along with high healthcare coverage. The need will be driven by neonatal examination, liver disease treatment, hospital chemistry, and elderly patients requiring repeated testing.

The dominant European nation will be Germany owing to the country's extensive hospital network, well-developed laboratory infrastructure, and strong medical technology manufacturing sector. The UK will maintain its demand using consolidated public laboratories and maternity units. France has public hospitals coupled with private diagnostic service providers, and Italy and Spain are upgrading their regional laboratory infrastructure and increasing instrument automation.

The European buyers will be increasingly evaluating environmental and operating performances along with clinical accuracy. Increased reagent shelf-life, decreased packaging, low volume sampling, efficient analyzers, and minimum repeats will help in improving tender performance. The companies having relevance in the region include Drägerwerk AG & Co. KGaA for neonatal applications, and F. Hoffmann-La Roche Ltd and Siemens Healthineers AG for automated diagnostic solutions.

APAC bilirubin blood test market

Asia Pacific accounted for ~25% of global revenue in 2025 and is forecast to register a ~9% CAGR through 2034, making it the fastest-growing region. China is the leading country in Asia Pacific, supported by its hospital network, domestic diagnostic manufacturing, and expanding laboratory automation.

Japan and South Korea emphasize high-quality automated testing, while India presents strong potential through diagnostic chains, maternal health programs, and wider access to newborn care. Australia has a mature pathology network with established quality requirements. Regional policy support for healthcare infrastructure, local production, and public diagnostics is improving the availability of serum tests and bilirubin instruments beyond major cities.

Middle East & Africa bilirubin blood test market

The Middle East & Africa market is expected to grow at a ~8% CAGR through 2034. Saudi Arabia is positioned as the leading country in the Middle East & Africa, supported by hospital development, laboratory modernization, and investment in maternal and neonatal services. The UAE benefits from advanced private hospitals and diagnostic infrastructure.

South Africa has a relatively developed laboratory network and serves as a distribution base for neighboring markets. Elsewhere, adoption varies because of differences in hospital access, laboratory staffing, instrument maintenance, energy reliability, and reagent logistics. Compact instruments, stable consumables, distributor training, and affordable service contracts can improve product utilization across resource-constrained facilities.

bilirubin-blood-test-market-cagr-image
Get a regional analysis of this market.
Download Free Sample Brochure

Segmentation Analysis

Test Type

Test type defines the clinical interpretation and bilirubin blood test market scope, as physicians may require an overall bilirubin measurement or fractionated results to investigate the underlying cause of jaundice. Selection depends on patient age, symptoms, suspected liver dysfunction, hemolysis risk, and laboratory protocol. The leading subsegment is projected to register a ~7% CAGR during 2026–2034, supported by its routine inclusion in liver panels and neonatal assessment workflows.

  • Total Serum Bilirubin Test: This test provides an overall bilirubin measurement and remains widely used for initial jaundice assessment, routine liver panels, newborn monitoring, and evaluation of suspected hepatic or hematological abnormalities.
  • Direct/Conjugated Bilirubin Test: Direct measurement supports the investigation of impaired bile excretion, cholestasis, obstruction, and hepatocellular dysfunction, helping clinicians differentiate conjugated hyperbilirubinemia from other causes of elevated bilirubin.
  • Indirect/Unconjugated Bilirubin Test: Indirect bilirubin assessment is relevant to hemolysis, impaired conjugation, and neonatal jaundice, with results commonly interpreted alongside total and direct bilirubin values and broader clinical findings.

Product Type

Product type reflects the relationship between recurring assay consumption and capital equipment purchasing. Hospitals and laboratories assess consumable stability, analyzer compatibility, calibration requirements, throughput, maintenance, and cost per result. Instruments influence long-term workflow architecture, while recurring materials determine ongoing operating expenditure. The leading subsegment is expected to record a ~7% CAGR during 2026–2034, supported by repeat testing, expanding installed equipment, and continued hepatic panel utilization.

  • Consumables: Reagents, calibration materials, quality controls, sample components, and device-specific supplies generate repeat purchases and allow manufacturers to develop recurring revenue from established instrument placements.
  • Instruments: Clinical chemistry analyzers, serum bilirubinometers, and other measurement systems support workflows ranging from centralized laboratory processing to rapid testing in maternity and neonatal care environments.

Age Group

Age group influences testing indication, specimen volume, reference interpretation, instrument selection, and care setting. Adult utilization is linked to hepatic, hematological, oncological, and medication-monitoring workflows, while pediatric demand emphasizes jaundice risk and limited-volume sampling. The higher-growth subsegment is forecast to advance at a ~8% CAGR during 2026–2034, reflecting wider institutional birth coverage, increased newborn surveillance, and investment in neonatal diagnostic capacity.

  • Pediatric/Infants: Testing supports early identification and monitoring of neonatal hyperbilirubinemia, with buyers emphasizing rapid results, small samples, atraumatic assessment, and products suited to maternity wards and intensive care.
  • Adults: Adult testing is embedded in routine hepatic panels and supports assessment of liver dysfunction, biliary obstruction, hemolysis, treatment effects, and disease progression across outpatient and inpatient settings.

Opportunity Snapshot

Age Group

Revenue Contribution

Trend Tag

Adoption Stage

Pediatric/Infants

Medium

Neonatal Screening

Scaling

Adults

High

Hepatic Panels

Mature

Request for Customization for extensive market insights.
Customize This Report

Bilirubin Blood Test Market Growth Drivers and Impact Analysis

Increasing Burden of Liver and Hepatobiliary Disorders

With more efforts being made to control the increasing cases of viral hepatitis, metabolic liver diseases, alcoholic liver disease, biliary problems, and other liver-related problems such as hepatotoxicity from drugs used in therapy, there is a growing need to perform liver assessments. Assessment of bilirubin levels is carried out in conjunction with liver enzyme assessment and other markers of liver function, thus becoming a recurrent process rather than a stand-alone test. The WHO surveillance on hepatitis takes into account the burden of the disease and access to essential services in 187 nations, emphasizing the need to grow further in terms of diagnosis and care.

Structured Assessment of Neonatal Jaundice

Persistent need for bilirubin analysis is observed in case of neonatal jaundice due to the necessity of the analysis of high bilirubin concentrations with respect to infant age, clinical risk, preterm birth, and feeding practices. Medical professionals perform screening tests via transcutaneous methods and blood tests in case of serum confirmation and therapy evaluation. Jaundice often occurs during the first period of an infant's life, especially among premature infants, and therefore requires frequent analyses in maternity wards and neonatal care departments. Institutional deliveries and neonatal capabilities growth will result in more testing opportunities in emerging countries. Bilirubin testing can be supported by manufacturers in several ways.

Automation of Clinical Chemistry Laboratories

Laboratory automation supports demand by processing bilirubin alongside broader hepatic and metabolic panels with limited manual intervention. Integrated systems can reduce sample handling, improve turnaround, standardize calibration, and manage workloads across core and satellite laboratories. Instrument upgrades also create recurring demand for compatible reagents, controls, and consumables. The commercial impact is strongest where diagnostic networks are consolidating and seeking common operating procedures across multiple sites. Vendors offering scalable analyzers, broad assay menus, remote service, inventory controls, and middleware integration can address both operational and clinical requirements. Smaller facilities remain relevant for compact systems that deliver automated performance without the footprint or capital requirements of high-throughput platforms.

Bilirubin Blood Test Market Future Trends

Integration of Noninvasive Screening with Confirmatory Testing

Future bilirubin blood test market trends will increasingly connect noninvasive newborn screening with confirmatory serum workflows. Transcutaneous instruments can identify infants who require further evaluation, while laboratory testing provides values for clinical decisions and ongoing monitoring. Emerging image-processing and artificial intelligence approaches are also being studied for bilirubin prediction from infant images, although clinical validation under varied lighting and skin tones remains essential. A 2025 study reported promising classification and regression performance from combined color-channel analysis, illustrating the direction of future innovation rather than immediate replacement of blood testing. Integrated pathways could reduce unnecessary blood draws while preserving confirmatory accuracy.

Connected, Sample-Efficient Diagnostic Systems

Next-generation systems are expected to emphasize smaller specimens, automatic patient identification, electronic result transfer, remote quality monitoring, and predictive inventory management. Sample efficiency is particularly important for premature infants and patients requiring repeated testing. Laboratories will also assess onboard reagent stability, calibration frequency, maintenance burden, consumable waste, and energy use when selecting equipment. Connectivity can help healthcare networks compare results across facilities and reduce transcription errors, but suppliers must address cybersecurity and interoperability. Products combining dependable analytical performance with simplified operation will be well positioned for decentralized laboratories, maternity facilities, and lower-throughput hospitals.

Bilirubin Blood Test Market Opportunities

Decentralized Neonatal Testing in Emerging Healthcare Systems

The bilirubin blood test market Forecasts indicate commercial opportunities for portable instruments and affordable consumables in regions expanding institutional maternity care. Manufacturers can develop compact systems for district hospitals, maternity centers, pediatric clinics, and mobile health programs where central laboratory access is limited. Key investment priorities include low sample requirements, temperature-tolerant consumables, battery-supported operation, intuitive interfaces, and straightforward quality control. Commercial strategies should include distributor training, maintenance coverage, clinical education, and local inventory. Partnerships with public maternal health programs and regional device suppliers can improve reach while addressing variations in reimbursement, procurement, infrastructure, and technical capability.

Integrated Liver Testing Portfolios

Diagnostic suppliers can expand beyond standalone bilirubin products by bundling total and fractionated bilirubin assays with liver enzymes, proteins, calibrators, controls, and data-management tools. Such portfolios can reduce procurement complexity and strengthen supplier relationships with hospital and reference laboratories. Investment opportunities include open-channel reagents for mixed analyzer fleets, dedicated packs for automated systems, and optimized volumes for facilities with lower throughput. Manufacturers may also differentiate through interference studies, extended reagent stability, service contracts, and standardized applications. A portfolio approach provides cross-selling potential while enabling laboratories to consolidate hepatic testing workflows and control the cost per reportable result.

Recent Developments

  • March 2025: Beckman Coulter, Inc. received US FDA clearance for the DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay system. The platform delivers up to 800 clinical chemistry tests and 100 immunoassay tests per hour, supporting laboratories seeking scalable workflows, common reagents, standardized reference ranges, and consolidated inventory management across networked facilities.
  • April 2025: Scientific Reports, a peer-reviewed study assessed artificial intelligence-based, noninvasive bilirubin prediction using infant image color channels and a convolutional neural network. The approach combined RGB and HSV information for bilirubin estimation and jaundice classification. Although investigational, the research indicates the future potential for image-assisted screening to complement clinical examination and confirmatory blood testing.
  • June 2024: F. Hoffmann-La Roche Ltd launched the cobas c 703 and cobas ISE neo analytical units for cobas pro integrated solutions in countries accepting the CE mark. The cobas c 703 provides up to 2,000 clinical chemistry tests per hour, 70 reagent positions, automated maintenance, and continuous reagent loading for high-volume laboratories.

Frequently Asked Questions

Asia Pacific is the fastest-growing region and is expected to register a ~9% CAGR through 2034. The growth outlook reflects expanding clinical laboratory capacity, maternal and neonatal healthcare investment, local diagnostic manufacturing, and improving access to automated chemistry testing across China, India, Japan, South Korea, and other regional markets.

North America held the largest regional position, accounting for approximately ~38% of global revenue in 2025. The region is projected to grow at a ~6% CAGR through 2034, supported by extensive laboratory automation, structured neonatal care, high diagnostic testing intensity, and established hospital and reference laboratory networks.

The market was valued at US$ 1.5 Billion in 2025 and is projected to reach US$ 2.72 Billion by 2034, expanding at a 6.86% CAGR during 2026–2034. Growth reflects recurring liver panel demand, neonatal bilirubin assessment, automated laboratory expansion, and wider access to diagnostic services.

The US accounted for approximately ~85% of North American revenue in 2025 and is forecast to register a ~6% CAGR through 2034. The bilirubin blood test market Report links this position to widespread analyzer deployment, large hospital networks, neonatal assessment practices, and frequent utilization of hepatic panels.

Consumables held approximately ~68% of market revenue in 2025 and are projected to expand at a ~7% CAGR through 2034. Their position reflects recurring expenditure on reagents, controls, calibration materials, cuvettes, and device-specific supplies required across the established base of laboratory and neonatal testing equipment.

The Pediatric/Infants segment represented approximately ~35% of revenue in 2025 and is expected to record a ~8% CAGR through 2034. Growth is supported by newborn jaundice assessment, expanding neonatal care capacity, wider institutional birth coverage, and demand for rapid, sample-efficient testing products.
Trupti Wadekar
Assistant Manager,
Market Research & Consulting

Trupti is a senior consultant with over 10 years of experience in the Healthcare sector, specializing in pharmaceuticals, biotechnology, and life-sciences markets. She holds a Bachelor’s degree in Biotechnology and an MBA with dual specialization in Marketing and Pharmaceuticals & Biotechnology, combining a strong scientific foundation with a strategic and commercial perspective. Her professional experience encompasses market research, competitive intelligence, strategic advisory, and business development, supporting clients across diverse and evolving healthcare markets.

She has worked extensively on market sizing and assessment, growth strategy, market expansion, and strategic decision-making initiatives, helping clients identify opportunities and address complex business challenges. Trupti brings strong expertise in client engagement, stakeholder management, team leadership, and translating research findings into actionable business insights. Her ability to connect scientific understanding with market dynamics and commercial strategy enables her to deliver practical, high-impact solutions aligned with client objectives.

  • Comprehensive Market Sizing and Forecast Analysis
  • Detailed Segmentation Analysis
  • In-Depth Market Dynamics Assessment
  • Regional and Country-Level Insights
  • Competitive Landscape and Company Benchmarking
  • Strategic Business Intelligence

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
DUNS Logo
ISO Certified Logo
GDPR
CCPA